Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2022 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma

BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
May 18, 2022 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology to Participate in Spring 2022 Investor Conferences

BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
May 12, 2022 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

IK-175 clinical trial combination expansion cohort in patients with urothelial carcinoma advanced to Stage 2 based on tolerability and preliminary anti-tumor activity First patients dosed in our...
May 02, 2022 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration

BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company forging new territory in patient-directed cancer treatment, and the Vall d’Hebron Institute...
April 28, 2022 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that...
April 13, 2022 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development

BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the...
March 07, 2022 16:30 ET | Source: Ikena Oncology, Inc.

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it...
December 08, 2021 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer

Dr. Zhang steps into the CSO role after spending more than five years at Ikena in research and development leadership Jeffrey Ecsedy, Ph.D., taking on newly created role as Chief Development...
November 12, 2021 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175

Data supports and describes the ongoing Phase 1a/b clinical trial of IK-175 as a single agent and in combination with nivolumab in advanced solid tumors Study evaluates IK-175 in urothelial carcinoma...
November 10, 2021 07:00 ET | Source: Ikena Oncology, Inc.

Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update

IND for IK-930 accepted by FDA; Phase 1 clinical trial expected to initiate in early 2022 Progressing RAS pathway research programs with multiple development candidates expected in the next 18 months...